公开(公告)号：US20220193070A1

公开(公告)日：2022-06-23

申请号：US17532909

申请日：2021-11-22

申请人： XENON PHARMACEUTICALS INC. ,  THE UNIVERSITY OF BRITISH COLUMBIA

发明人： Robin Paul SHERRINGTON ,  Mary B. CONNOLLY

IPC分类号： A61K31/495 ,  A61P25/08

摘要： In certain embodiments, the present disclosure is directed to methods and uses of flunarizine, including for treating absence seizures in a human patient, such as absence seizures in childhood absence epilepsy (CAE), wherein the methods comprise administering (e.g., orally) to a patient in need thereof a therapeutically effective amount of flunarizine. The present disclosure is further directed to various improved methods of therapy and administration of flunarizine.

公开(公告)号：US11203572B2

公开(公告)日：2021-12-21

申请号：US17011355

申请日：2020-09-03

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Ivan William Hemeon ,  Steven McKerrall ,  Daniel Sutherlin

IPC分类号： C07C381/10 ,  C07D401/12 ,  C07D205/04 ,  C07D211/22 ,  C07D211/42 ,  C07D213/69 ,  A61P25/04

摘要： The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10745392B2

公开(公告)日：2020-08-18

申请号：US16440459

申请日：2019-06-13

申请人： Xenon Pharmaceuticals Inc.

发明人： Kristen Nicole Burford ,  Thilo Focken ,  Verner Alexander Lofstrand ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC分类号： C07D417/12 ,  A61P25/08 ,  C07D277/52 ,  C07D413/12

摘要： This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20200157089A1

公开(公告)日：2020-05-21

申请号：US16556055

申请日：2019-08-29

申请人： Xenon Pharmaceuticals Inc.

发明人： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC分类号： C07D417/14 ,  C07D417/12 ,  C07D401/14 ,  C07D401/12 ,  C07D409/12 ,  C07D487/08 ,  C07D471/04 ,  C07D413/12

摘要： This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20200071313A1

公开(公告)日：2020-03-05

申请号：US16555983

申请日：2019-08-29

申请人： Xenon Pharmaceuticals Inc.

发明人： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson

IPC分类号： C07D417/14 ,  C07D409/14 ,  C07D401/14 ,  A61P25/08 ,  C07C53/18

摘要： This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

公开(公告)号：US20200030260A1

公开(公告)日：2020-01-30

申请号：US16523568

申请日：2019-07-26

申请人： Xenon Pharmaceuticals Inc.

发明人： Robin Paul Sherrington ,  Jean-Jacques Alexandre Cadieux ,  Parisa Karimi Tari ,  Jeffrey Paul Bechard

IPC分类号： A61K31/137 ,  A61K31/24 ,  A61P25/08

摘要： In certain embodiments, the present disclosure is directed to methods and uses for treating a mammal having an epileptic seizure disorder or being at risk for having an epileptic seizure disorder, comprising administering certain herein disclosed isolated fenfluramine enantiomers that are surprisingly effective as anti-epilepsy drugs (AEDs), despite having lower anti-seizure potency than fenfluramine racemate, by virtue of also being less cardiotoxic than fenfluramine racemate. Preferred embodiments contemplate treatment of Dravet syndrome; other preferred embodiments contemplate treatment of other epileptic seizure disorders.

公开(公告)号：US20190031607A1

公开(公告)日：2019-01-31

申请号：US16150070

申请日：2018-10-02

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Jean-Christophe ANDREZ ,  Philippe BERGERON ,  Paul Robert BICHLER ,  Sultan CHOWDHURY ,  Christoph Martin DEHNHARDT ,  Thilo FOCKEN ,  Wei GONG ,  Michael Edward GRIMWOOD ,  Abid HASAN ,  Ivan William HEMEON ,  Qi JIA ,  Brian Salvatore SAFINA ,  Shaoyi SUN ,  Michael Scott WILSON ,  Alla Yurevna ZENOVA

IPC分类号： C07D207/16 ,  C07C235/52 ,  C07D209/02 ,  C07D401/10 ,  C07D205/04 ,  C07D207/22 ,  C07D211/20 ,  C07C235/42 ,  C07D211/38 ,  C07D409/06 ,  C07D265/30 ,  C07D413/12 ,  C07D263/26 ,  C07C235/54 ,  C07D417/12 ,  C07D305/08 ,  C07D213/69 ,  C07D403/04 ,  C07D231/06 ,  C07D209/52 ,  C07D221/22 ,  C07D209/54 ,  C07D403/12 ,  C07D211/60 ,  C07D207/10 ,  C07D401/12 ,  C07D471/08 ,  C07D413/14 ,  C07D207/08 ,  C07D405/10 ,  C07D403/14 ,  C07D451/02 ,  C07D401/14 ,  C07D263/04 ,  C07D277/06

CPC分类号： C07D207/16 ,  C07C235/42 ,  C07C235/52 ,  C07C235/54 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2603/74 ,  C07D205/04 ,  C07D207/08 ,  C07D207/10 ,  C07D207/22 ,  C07D209/02 ,  C07D209/52 ,  C07D209/54 ,  C07D211/20 ,  C07D211/38 ,  C07D211/60 ,  C07D213/69 ,  C07D221/22 ,  C07D231/06 ,  C07D263/04 ,  C07D263/26 ,  C07D265/30 ,  C07D277/06 ,  C07D305/08 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/10 ,  C07D409/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D451/02 ,  C07D471/08

摘要： The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20180346416A1

公开(公告)日：2018-12-06

申请号：US16057693

申请日：2018-08-07

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Christoph Martin DEHNHARDT ,  Sultan CHOWDHURY ,  Thilo FOCKEN ,  Michael Edward GRIMWOOD ,  Ivan William HEMEON ,  Brian Salvatore SAFINA ,  Daniel P. SUTHERLIN

IPC分类号： C07C307/06 ,  C07D277/24 ,  C07D401/12 ,  C07D305/08 ,  C07D213/64 ,  C07D213/63 ,  C07D277/62 ,  C07D277/34 ,  C07D405/12 ,  C07D231/56 ,  C07D215/20 ,  C07D213/74 ,  C07D213/69 ,  C07D209/08 ,  C07D205/04 ,  C07D413/12 ,  C07D217/02

CPC分类号： C07C307/06 ,  C07C2601/04 ,  C07D205/04 ,  C07D209/08 ,  C07D213/63 ,  C07D213/64 ,  C07D213/69 ,  C07D213/74 ,  C07D215/20 ,  C07D217/02 ,  C07D231/56 ,  C07D277/24 ,  C07D277/34 ,  C07D277/62 ,  C07D305/08 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12

摘要： The invention provides methods for treating pain using compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described herein.

公开(公告)号：US20180230079A1

公开(公告)日：2018-08-16

申请号：US15896970

申请日：2018-02-14

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Ivan William HEMEON ,  Brian SAFINA ,  Daniel SUTHERLIN

IPC分类号： C07C62/38 ,  C07C62/34 ,  C07D211/22 ,  C07C323/61 ,  C07C317/44 ,  C07C313/04 ,  C07C229/48 ,  A61P17/04 ,  A61P25/00 ,  A61P29/00

CPC分类号： C07C62/38 ,  A61P17/04 ,  A61P25/00 ,  A61P29/00 ,  C07C62/34 ,  C07C69/757 ,  C07C229/48 ,  C07C313/04 ,  C07C317/44 ,  C07C323/61 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D211/22

摘要： The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US09546164B2

公开(公告)日：2017-01-17

申请号：US14603273

申请日：2015-01-22

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Jean-Christophe Andrez ,  Paul Robert Bichler ,  Chien-An Chen ,  Sultan Chowdhury ,  Shannon Marie Decker ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Ivan William Hemeon ,  Qi Jia ,  Jun Li ,  Zhiguo Liu ,  Daniel F. Ortwine ,  Brian Safina ,  Daniel Sutherlin ,  Tao Sheng ,  Shaoyi Sun ,  Andrew D. White ,  Michael Scott Wilson ,  Alla Yurevna Zenova ,  Jiuxiang Zhu

IPC分类号： C07D211/32 ,  C07D211/54 ,  C07D233/68 ,  C07D453/02 ,  A61K31/337 ,  A61K31/397 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4412 ,  A61K31/495 ,  C07D237/08 ,  C07D241/04 ,  C07D205/04 ,  C07D207/12 ,  C07D211/42 ,  C07D305/08 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D403/04 ,  C07D487/08 ,  C07D265/30 ,  C07D211/60

CPC分类号： A61K31/445 ,  A61K31/337 ,  A61K31/397 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4412 ,  A61K31/4523 ,  A61K31/4545 ,  A61K31/495 ,  C07D205/04 ,  C07D207/12 ,  C07D211/22 ,  C07D211/32 ,  C07D211/42 ,  C07D211/54 ,  C07D211/60 ,  C07D233/68 ,  C07D237/08 ,  C07D241/04 ,  C07D265/30 ,  C07D305/08 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D453/02 ,  C07D487/08 ,  C07F7/0812

摘要： The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

摘要翻译： 本发明提供具有通式I的化合物及其药学上可接受的盐，其中变量RA，RAA，下标n，环A，X2，L，下标m，X1，R1，R2，R3，R4，R5和RN 具有本文所述的含义，以及含有这些化合物的组合物和使用这些化合物和组合物的方法。